Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projectsSignificant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoing with more than 80 patients recruited and the technology transfer to Biogen Inc. for the production of clinical material has been completed.Preclinical data presented at scientific conferences:• ATOR-1015 localizes to the tumor and selectively activates the immune system in the tumor, confirming the intended mechanism of action.• ATOR-1017 potently activates T cells and NK cells, both important for immune-mediated tumor cell killing. The results